January 19, 2021, Vol 325, No. 3, Pages 205-316
The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials
Annette Rid, MD; Marc Lipsitch, DPhil; Franklin G. Miller, PhD
free access has active quiz has multimedia has audio
JAMA. 2021;325(3):219-220. doi:10.1001/jama.2020.25053
This Viewpoint proposes that prioritizing all placebo-group participants in coronavirus vaccine trials as vaccine first receivers could perpetuate health inequities and compromise the chance to learn from their participation, proposing instead to limit prioritization to placebo participants who would be prioritized for vaccination anyway under NASEM or ACIP frameworks.
Conversations with Dr Bauchner: Coronavirus Vaccine FDA Update
Conversations with Dr Bauchner: COVID-19 Vaccines and Herd Immunity